Estimated Cost of Overactive Bladder in Thailand
Kriangsak Prasopsanti MD*, Apirak Santi-Ngamkun MD*, Kanokwan Pornprasit MD**
Affiliation : * Division of Urology, Department of Surgery, King Chulalongkorn Memorial Hospital, Bangkok ** Medical Department, Pfizer (Thailand) Limited
Objective : To estimate the annual direct and indirect costs of overactive bladder (OAB) in indigenous Thai
people aged 18 years and over in the year 2005.
Materials and Methods : Economically based models using diagnostic and treatment algorithms from clinical
practice guidelines and current disease prevalence data were used to estimate direct and indirect costs of
OAB. Prevalence and event probability estimates were obtained from the literature, national data sets, and
expert opinion. Costs were estimated from a small survey using a cost questionnaire and from unit costs of
King Chulalongkorn Memorial Hospital.
Results : The annual cost of OAB in Thailand is estimated as 1.9 billion USD. It is estimated to consume 1.14%
of national GDP. The cost includes 0.33 billion USD for direct medical costs, 1.3 billion USD for direct, non-
medical costs and 0.29 billion USD for indirect costs of lost productivity. The largest costs category was direct
treatment costs of comorbidities associated with OAB. Costs of OAB medication accounted for 14% of the total
costs of OAB.
Keywords : Overactive bladder, Annual cost, Direct cost, Indirect cost
